Cartesian Therapeutics, Inc.
RNAC
NASDAQ·Healthcare·Biotechnology·Mkt cap $272.4M
$9.27
▲ +1.64%
P/E
-1.59
Mkt Cap
$272.4M
52-Wk Range
$5.60–$11.00
52-Week Range
$5.60 - $11.00
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 9.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Proprietary nanoparticle immunomodulatory technology platform with broad therapeutic applications
- Strategic partnerships with pharmaceutical giants (Takeda, Astellas, Sarepta) and research institutions (MIT)
- Diverse pipeline addressing underserved rare diseases with limited treatment options and high unmet medical needs
Bear Case
1 risk
- Low volatility (beta 0.6).
Growth
Revenue decline expected
Advancement of SEL-212 through Phase III trials for chronic refractory gout with significant market opportunity
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+58.2% over 3m
Quality
Loss-making
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying RNAC right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 6, 2026
Reported EPS of $0.46 vs -$0.88 consensus (+152.4% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+152.4%
Revenue trend · last 8Q
—
-109%
-81%
-99%
+17%
—
-93%
-100%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$387.0K
-$759.0K
$1.1M
$298.0K
$452.0K
$947.0K
$78.0K
$0
Margins · last 8Q
Gross
—
Profit
—
Wall Street consensus
3 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Wedbush · May 27, 2026
vs Industry
How RNAC stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related